Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review
Open Access
- 10 March 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 824308
Abstract
Immune checkpoint inhibitor (ICI) treatment has dramatically revolutionized the landscape of therapeutic approaches in multiple cancers, particularly, non-small-cell lung cancer (NSCLC). With the increasing use of programmed death-1 (PD-1) inhibitors in the clinic, the emerging toxicity profile presents a novel learning curve for clinicians. Here we report the first case of an NSCLC patient displaying sarcoid/granulomatous-like reaction (SLR, also known as GLR) in the liver during an anti-PD-1 therapy which showed efficacious response of complete regression. Also, this is the first report describing the SLR induced by toripalimab, a novel PD-1 inhibitor. Given this kind of hepatic findings can be easily mistaken as metastasis, even resulting in premature use of second-line treatments. In particular, we briefly review the clinical features of all those cases reporting sarcoidosis and SLRs manifested on different organs during anti-PD-(L)1 therapy. We anticipate that these clinical cases would help to alert the attention of clinicians that SLRs, as a rare immune-related adverse event (irAE), is manageable and that histopathological analysis is necessary before interpreting it as disease progression.Keywords
This publication has 69 references indexed in Scilit:
- Pulmonary sarcoid-like granulomatosis induced by nivolumabBritish Journal of Dermatology, 2016
- Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced MelanomaChest, 2016
- Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumabAnnals of Oncology, 2016
- Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell DisordersAmerican Journal of Surgical Pathology, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumabOncoImmunology, 2014
- New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody TreatmentOncology Research and Treatment, 2014
- Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumabJournal of the American Academy of Dermatology, 2013
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete RemissionJournal of Clinical Oncology, 2012
- Co-existing Sarcoidosis Confounds the Staging of Bilateral Renal Cell CarcinomaJournal of Radiology Case Reports, 2011